What Epic Therapeutics does

EPICS Therapeutics SA is a Belgian clinical-stage biotechnology company founded in April 2018 and headquartered in Gosselies, Belgium. The company develops a pipeline of small-molecule therapeutics targeting RNA epigenetic regulation — specifically the m6A epitranscriptome via METTL3 inhibition — and complementary G-protein-coupled receptor (GPCR) pathways for the treatment of cancer and autoimmune/inflammatory disease. Its lead clinical candidate, EP102, is an oral, selective, best-in-class METTL3 inhibitor that entered first-in-patient trials in September 2025 across 12 hospital sites in 5 European countries (Belgium, Netherlands, Spain, Czech Republic, France), targeting advanced solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancer. The pipeline also includes EP282, a first-in-class oral FFAR2 agonist for autoimmune disease (Phase I completed, positioned as Phase II-ready), and EP601, an oral GPR84 agonist in preclinical development for immuno-oncology and neuroinflammation. EPICS also operates the wholly-owned EuroscreenFast Business Services Unit, which offers GPCR screening services to external pharma and biotech clients.

The company's underlying technology platforms combine an "epitranscriptome" target class (RNA-modifying enzymes that write, read, or erase m6A marks) with GPCR modulation, intentionally positioning the company beyond DNA- and protein-targeted approaches. Pipeline assets were largely seeded by the December 2018 acquisition of Ogeda SA's assets, and the operational team — including the inventor of fezolinetant — carries significant prior drug-development experience.

The business model is pre-revenue and discovery-and-development oriented, with future revenue expected to come from product sales following regulatory approval and potential licensing or partnership transactions. There is no direct pricing or commercial sales operation; distribution today occurs via regulated clinical trial channels in Europe, with an additional service-revenue stream from EuroscreenFast's GPCR screening unit. Go-to-market is enterprise-style, with direct engagement of oncology Key Opinion Leaders, academic medical centers, and regulators, supplemented by scientific conferences (AACR, ASH, EORTC), peer-reviewed publications, and BIO investment conventions for investor and partner visibility.

Name

Epic Therapeutics

Legal name

Epics Therapeutics SA

Website

https://epicstherapeutics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Epic Therapeutics (EPICS) is a Belgian clinical-stage biotechnology company developing small-molecule METTL3 inhibitors (lead EP102) and GPCR modulators (EP282, EP601) to treat advanced solid tumors and autoimmune/inflammatory diseases. Founded 2018, headquartered in Gosselies, Belgium; lead asset entered first-in-patient trials in 2025.

Ownership category

akta.pro rank

Product category

Clinical-Stage Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI)

Keywords

• Small molecule therapeutics
• RNA epigenetics drugs
• METTL3 inhibitor oncology
• Clinical stage biotechnology
• Epitranscriptome drug discovery

Headquarters

HQ city

Gosselies

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Drug Development: EPICS Therapeutics is a pre-revenue clinical-stage biotechnology company developing small molecule therapeutics. Revenue will be generated through product sales following regulatory approval, as well as potential licensing deals and partnerships for its pipeline programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Epic Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs targeting RNA epigenetics (epitranscriptome) and GPCR pathways for cancer and autoimmune disease. Its lead asset EP102 is a best-in-class, orally available METTL3 inhibitor now in first-in-patient clinical evaluation in solid tumors (NSCLC, pancreatic, ovarian, colorectal), supported by Phase II-ready EP282 (FFAR2 agonist) and preclinical EP601 (GPR84 agonist).

Product overview

EPICS Therapeutics is a clinical-stage biotechnology company developing a pipeline of small-molecule drugs targeting RNA epigenetics and G-protein-coupled receptor (GPCR) mechanisms for cancer and autoimmune disease treatment. The core portfolio includes EP102 (METTL3 inhibitor, first-in-patient clinical trial for solid tumors), EP282 (FFAR2 agonist, Phase II ready for autoimmune diseases), and EP601 (GPR84 agonist, preclinical for oncology and autoimmune diseases). The RNA epigenetics platform targets the epitranscriptome to modulate RNA processing and gene expression, while the GPCR program extends this epigenetic vision to complementary signaling pathways.

Differentiator

Problem solved

Functional benefit

Products and services

• EP102 (METTL3 Inhibitor) Best-in-class, potent, selective, and orally available small-molecule inhibitor of the METTL3 enzyme that installs the m6A mark on messenger RNA, reprogramming tumor biology at the RNA level. EP102 is the company's lead clinical candidate for advanced solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancers.
• EP282 (FFAR2 Agonist) First-in-class small-molecule FFAR2 (Free Fatty Acid Receptor 2) agonist targeting the microbiome-immune axis for treatment of autoimmune and inflammatory diseases, including ulcerative colitis and C. difficile infection; also has potential in colorectal cancer. Ready for Phase II clinical development.
• EP601 (GPR84 Agonist) Potent, selective, and orally available GPR84 agonist designed to activate or restrain immune responses, positioned at the intersection of metabolism, inflammation, and innate immunity, with therapeutic potential in oncology (tumor microenvironment reprogramming) and autoimmune diseases. In active preclinical development.
• EuroscreenFast GPCR Screening Services GPCR screening and assay development services offered to worldwide pharma and biotech clients through Epic's wholly-owned EuroscreenFast Business Services Unit.

Quantifiable outcome

• EP102 demonstrated near-complete tumor growth suppression in xenograft studies
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, major and supporting.

• Cresset DiscoverycoreTechnology or Integration · 8 December 2025Computational drug design partnership where Cresset's integrated modeling workflow combining molecular modeling and proprietary technology (Electrostatic Complementarity) accelerated the discovery and optimization of EPICS' METTL3 inhibitor compounds. The iterative process of in silico design and biological testing supported efficient hit identification and lead optimization.
• Ogeda SA (Astellas acquisition)majorStrategic or Co-development PartnerEPICS acquired Ogeda SA's former assets in December 2018, including research stage programs and the EuroscreenFast Business Services Unit. Ogeda's former CEO Jean Combalbert became CEO of EPICS. Several key EPICS team members (including Graeme Fraser, Guillaume Dutheuil, Vincent Lannoy, Catherine Sorlet) previously worked at Ogeda, which was acquired by Astellas for 800M EUR in 2017.
• François Fuks (ULB Cancer Research Center)coreStrategic or Co-development PartnerClinical Scientific Advisor to EPICS - Professor at Free University of Brussels and Director of ULB Cancer Research Center. His work is devoted to epigenetics and its role in cancer. Performed doctoral research at German Cancer Research Center under Harald zur Hausen (2008 Nobel Prize in Medicine). Serves as scientific founder/advisor providing expertise in epigenetics.
• Memorial Sloan Kettering Cancer Center (MSK) - David Scheinberg & Omar Abdel-WahabcoreStrategic or Co-development PartnerClinical Advisory Board members from MSK: David A. Scheinberg (Vincent Astor Chair, Deputy Director for Therapeutic Discovery at Sloan Kettering Institute) and Omar Abdel-Wahab (Evin Family Chair of Molecular Pharmacology, Chair of Molecular Pharmacology Program). Both are physician-scientists specializing in novel therapeutic approaches for leukemia and cancer with extensive research programs.
• VHIO (Vall d'Hebron Institute of Oncology) - Elena GarraldacoreStrategic or Co-development PartnerClinical Advisory Board member Elena Garralda serves as Director of Molecular Cancer Therapy Research Unit (UITM) - CaixaResearch, Co-Director of Clinical Research Program, and Head of Early Drug Development at VHIO. She coordinates phase I program with expertise in immuno-oncology and first-in-human studies.
• Curve Therapeutics - Rab PrinjhasupportingStrategic or Co-development PartnerClinical Advisory Board member Rab Prinjha is currently Chief Research and Development Officer at Curve Therapeutics, former head of GSK's Immunology Research Unit and elected fellow of the Academy of Medical Sciences. Has extensive record of successful leadership with multiple first-in-class epigenetic target inhibitors progressed from discovery to beyond Phase 2.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• STORM Therapeutics: STORM Therapeutics is the closest direct competitor to EPICS in RNA epitranscriptomics, developing small-molecule METTL3 inhibitors (STC-15) that are also in Phase I clinical trials for solid tumors and leukemia. Both companies target the same epitranscriptome mechanism with oral small molecules.
• Accent Therapeutics: Accent Therapeutics develops precision oncology drugs targeting RNA-modifying proteins including METTL3 and other epitranscriptome regulators. As a US-based, well-capitalized competitor in the same therapeutic axis, it is directly comparable to EPICS' EP102 program.
• Domain Therapeutics: Domain Therapeutics is a French biotech specializing in GPCR drug discovery and development, directly comparable to EPICS' GPCR programs (EP282 FFAR2, EP601 GPR84) and its inherited EuroscreenFast GPCR screening capabilities. Both operate in European biotech ecosystems with similar GPCR target portfolios.
• Twentyeight-Seven Therapeutics: Twentyeight-Seven Therapeutics focused on RNA modifying proteins (initially METTL3) for oncology before being acquired by Roche. Directly comparable to EPICS as a small-molecule developer targeting RNA epigenetic regulators in cancer.

Emerging players

• Tango Therapeutics: Tango Therapeutics is a clinical-stage oncology biotech focused on synthetic lethal targets, with a similar small-molecule targeted oncology strategy and similar stage profile as EPICS. While mechanism differs, the business model and target patient populations overlap substantially.
• Repare Therapeutics: Repare Therapeutics develops precision oncology drugs targeting DNA damage response pathways — directly overlapping with EPICS' positioning of EP102 in tumors where METTL3 dysregulation intersects with DDR pathways. Both companies are clinical-stage with similar oncology indications in scope.

Broad incumbents

• Sosei Heptares: Sosei Heptares is a leading GPCR-targeted therapeutics company with a broader portfolio than EPICS' GPCR programs (EP282, EP601). It provides a benchmark for the commercial potential of GPCR-focused drug discovery and is comparable on the GPCR technology axis.
• Blueprint Medicines: Blueprint Medicines is a larger precision oncology company with approved targeted small-molecule therapies. While targeting different mechanisms, it serves as a comparable business model benchmark for clinical-stage-to-commercial targeted oncology biotechs in EPICS' competitive set.

Regional players

• iTeos Therapeutics: iTeos Therapeutics is a Belgian clinical-stage immuno-oncology biotech. While its mechanism differs, it shares EPICS' Belgian biotech ecosystem, similar company stage profile, and similar oncology-focused small-molecule pipeline approach.
• Crescendo Biologics: Crescendo Biologics is a UK-based clinical-stage biotech with T-cell engagers in oncology. Comparable as a European clinical-stage oncology biotech with similar headcount scale and capital profile, though addressing different mechanisms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/epics-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epic Therapeutics